Delta neutrophil index is an independent predictor of mortality in septic acute kidney injury patients treated with continuous renal replacement therapy

作者:Han In Mi; Yoon Chang Yun; Shin Dong Ho; Kee Youn Kyung; Han Seung Gyu; Kwon Young Eun; Park Kyoung Sook; Lee Mi Jung; Oh Hyung Jung; Park Jung Tak; Han Seung Hyeok; Kang Shin Wook; Yoo Tae Hyun
来源:BMC Nephrology, 2017, 18(1): 94.
DOI:10.1186/s12882-017-0507-8

摘要

Background: Delta neutrophil index (DNI), representing an elevated fraction of circulating immature granulocytes in acute infection, has been reported as a useful marker for predicting mortality in patients with sepsis. The aim of this study was to evaluate the prognostic value of DNI in predicting mortality in septic acute kidney injury (S-AKI) patients treated with continuous renal replacement therapy (CRRT). Method: This is a retrospective analysis of consecutively CRRT treated patients. We enrolled 286 S-AKI patients who underwent CRRT and divided them into three groups based on the tertiles of DNI at CRRT initiation (high, DNI > 12. 0%; intermediate, 3.6-12.0%; low, < 3.6%). Patient survival was estimated with the Kaplan-Meier method and Cox proportional hazards models to determine the effect of DNI on the mortality of S-AKI patients. Results: Patients in the highest tertile of DNI showed higher Acute Physiology and Chronic Health Evaluation II score (highest tertile, 27.9 +/- 7.0; lowest tertile, 24.6 +/- 8.3; P = 0.003) and Sequential Organ Failure Assessment score (highest tertile, 14.1 +/- 3.0; lowest tertile, 12.1 +/- 4.0; P = 0.001). The 28-day mortality rate was significantly higher in the highest tertile group than in the lower two tertile groups (P < 0.001). In the multiple Cox proportional hazard model, DNI was an independent predictor for mortality after adjusting multiple confounding factors (hazard ratio, 1.010; 95% confidence interval, 1.001-1.019; P = 0.036). Conclusion: This study suggests that DNI is independently associated with mortality of S-AKI patients on CRRT.

  • 出版日期2017-3-20